Global Transcutaneous Jaundice Device Market Strategic Research Report

Scope of the Report

The global Transcutaneous Jaundice Device market size is predicted to grow from US$ 103 million in 2025 to US$ 111 million in 2032; it is expected to grow at a CAGR of 1.4% from 2026 to 2032.

The core drivers of the development of the transcutaneous bilirubin meter industry are twofold. First, the high incidence of neonatal jaundice creates a rigid clinical demand. The prevalence of jaundice in full-term and premature infants makes non-invasive and rapid testing equipment a necessity for neonatal health protection. Second, policy-driven improvements in the neonatal disease screening capabilities of primary healthcare systems, with relevant regulations listing transcutaneous bilirubin testing as a recommended method, coupled with the popularization and upgrading of equipment in primary healthcare institutions, continue to release market demand.

In 2024, global Transcutaneous Jaundice Device reached approximately 55,813 Units, with an average global market price of around 1,918.0 USD per Unit.

Transcutaneous Jaundice Device are non-invasive medical devices used to measure the level of bilirubin in a patient’s skin, primarily in neonates, to assess the risk of jaundice. These meters work by using light to estimate the bilirubin concentration in the subcutaneous tissue, which can be an indicator of the liver's ability to process bilirubin.

Transcutaneous bilirubin measurement is performed by placing a sensor on the baby’s skin, usually on the forehead or chest, where the skin is thin. The device emits light at specific wavelengths, and based on the amount of light that is absorbed or reflected by the skin, the device calculates the bilirubin level. This method provides a quick, painless alternative to serum bilirubin tests, reducing the need for blood draws.

The upstream core components of Transcutaneous Jaundice Device mainly include light sources, photoelectric sensors, filters, microprocessors, etc. Typical suppliers include Hamamatsu Photonics, Nichia, Edmund Optics, Thorlabs, etc. The downstream applications are mainly in hospitals, clinics, community service centers, and postpartum care centers.

The single-line production capacity of Transcutaneous Jaundice Device varies significantly depending on the manufacturer's scale, product positioning, and production model. Typically, the single-line production capacity of regular products is over 2,000 units, and the industry gross profit margin is in the range of 40%-60%.

Transcutaneous Jaundice Device are non-invasive sentinels protecting newborn health. Designed specifically for neonatal jaundice screening, these medical devices utilize spectral absorption technology. Simply place the probe lightly against the infant's forehead or sternum, and within seconds, the difference in reflection between blue and green light is used to calculate bilirubin levels, completely eliminating the pain and waiting associated with traditional blood tests. From bedside screening in maternity wards to routine monitoring in primary care hospitals and home follow-up, this device, with its non-invasive, rapid, and safe characteristics, has become a key tool for the early detection and intervention of neonatal hyperbilirubinemia, building the first line of defense for the health of millions of newborns worldwide.

The global market for Transcutaneous Jaundice Device exhibits a distinct regional development pattern. North America, relying on its mature neonatal healthcare system and high medical investment, has stable and concentrated market demand. Local companies have accumulated deep expertise in device intelligence and clinical adaptability, occupying a core position in the global market. Europe excels in technological precision, with stringent medical standards driving equipment upgrades towards low-interference, high-precision solutions. Products not only serve the well-developed local healthcare network but also radiate globally through technology exports. The Asia-Pacific region has become the core engine of industry growth. China, with its large newborn population and policies promoting the widespread availability of basic medical equipment, has propelled domestic brands from followers to leaders. Meanwhile, emerging markets such as India and Southeast Asia, with their improving healthcare infrastructure, are releasing strong incremental demand. According to our data, in 2024, Asia held nearly 50% of the market share for Transcutaneous Jaundice Device, followed by Europe and North America. During the forecast period, emerging markets such as India and Southeast Asia are leading the global growth rate.

From a manufacturer perspective, globally, key manufacturers of Transcutaneous Jaundice Device include Dräger, Mennen Medical, Philips, Konica Minolta, Beijing Maibang Optoelectronics, Ningbo Davy Medical, Weicai, AVI Healthcare, NEORUBIN (RECOVE GROUP), Nanjing Daofen Electronics, Likang Biotechnology, Boke Biotechnology, and Micro Lab. According to our data, the top 5 manufacturers accounted for over 70% of the global market share in 2024.

The convergence of multiple demands and policies has injected continuous growth momentum into the Transcutaneous Jaundice Device industry. The high incidence of neonatal jaundice forms a rigid demand foundation, while the monitoring needs of premature and high-risk infants further make the equipment a clinical necessity. At the policy level, countries are incorporating neonatal disease screening into their public health systems, while technological innovation is reshaping product value. Multi-wavelength spectral technology overcomes the bottleneck of skin color interference, and intelligent algorithms enable real-time data transmission and trend prediction, upgrading the equipment from a simple testing tool to an entry point for neonatal health management. Meanwhile, the public's growing preference for non-invasive medical care and increased awareness of home health monitoring have further broadened application scenarios, extending from hospitals to homes and forming a full-cycle monitoring ecosystem.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Transcutaneous Jaundice Device market?

What factors are driving Transcutaneous Jaundice Device market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Transcutaneous Jaundice Device market opportunities vary by end market size?

How does Transcutaneous Jaundice Device break out by Type, by Application?

This report presents a comprehensive overview of the global Transcutaneous Jaundice Device market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Standard Type
• Intelligent Type

Segment by Technology

• Single Measurement Optical Path
• Dual Measurement Optical Path

Segment by Power Supply

• Rechargeable Type
• Non-rechargeable Type

Segment by Application

• Hospitals
• Clinics
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Transcutaneous Jaundice Device market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Clinics, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact